Evidence map›Paper›PMID 37561179›Full record

ArticleApplied microbiology and biotechnology2023

Lipopeptides from an isolate of Bacillus subtilis complex have inhibitory and antibiofilm effects on Fusarium solani.

Daniélle Santos-Lima, Cristina de Castro Spadari, Vinícius de Morais Barroso, Juliana C S Carvalho, Larissa Costa de Almeida, Felipe Santiago Chambergo Alcalde, Marcelo José Pena Ferreira, Miriam Sannomiya, Kelly Ishida

Abstract read
PubMed Publisher
In one paragraph

Article in Applied microbiology and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
4.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Lipopeptides fromBiotech (Basel (Switzerland)) · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Daniélle Santos-LimaInstitute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Cristina de Castro SpadariInstitute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Vinícius de Morais BarrosoInstitute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Juliana C S CarvalhoInstitute of Biosciences, University of São Paulo, São Paulo, SP, Brazil.
Larissa Costa de AlmeidaInstitute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
Felipe Santiago Chambergo AlcaldeSchool of Arts, Sciences and Humanities, University of São Paulo, Arlindo Béttio St. 1000, São Paulo, SP, 03828-000, Brazil.
Marcelo José Pena FerreiraInstitute of Biosciences, University of São Paulo, São Paulo, SP, Brazil.
Miriam SannomiyaSchool of Arts, Sciences and Humanities, University of São Paulo, Arlindo Béttio St. 1000, São Paulo, SP, 03828-000, Brazil. miriamsan@usp.br.
Kelly IshidaInstitute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil. ishidakelly@usp.br.ORCID http://orcid.org/0000-0002-4602-0926
Universidade de São Paulo · BR

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 140120/2018-1Conselho Nacional de Desenvolvimento Científico e Tecnológico 150534/2022-1Conselho Nacional de Desenvolvimento Científico e Tecnológico 306041/2022-7Conselho Nacional de Desenvolvimento Científico e Tecnológico 308952/2020-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 405556/2018-7Coordenação de Aperfeiçoamento de Pessoal de Nível Superior finance code 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/11612-0Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/16554-9Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/01279-5
6 · The paper itself

Abstract

Bacillus subtilis species complex is known as lipopeptide-producer with biotechnological potential for pharmaceutical developments. This study aimed to identify lipopeptides from a bacterial isolate and evaluate their antifungal effects. Here, we isolated and identified a lipopeptide-producing bacterium as a species of Bacillus subtilis complex (strain UL-1). Twenty lipopeptides (six iturins, six fengycins, and eight surfactins) were identified in the crude extract (CE) and fractions (F1, F2, F3, and F4), and the highest content of total lipopeptides was observed in CE and F2. The chemical quantification data corroborate with the hemolytic and antifungal activities that CE and F2 were the most hemolytic and inhibited the fungal growth at lower concentrations against Fusarium spp. In addition, they caused morphological changes such as shortening and/or atypical branching of hyphae and induction of chlamydospore-like structure formation, especially in Fusarium solani. CE was the most effective in inhibiting the biofilm formation and in disrupting the mature biofilm of F. solani reducing the total biomass and the metabolic activity at concentrations ≥ 2 µg/mL. Moreover, CE significantly inhibited the adherence of F. solani conidia on contact lenses and nails as well as disrupted the pre-formed biofilms on nails. CE at 100 mg/kg was nontoxic on Galleria mellonella larvae, and it reduced the fungal burden in larvae previously infected by F. solani. Taken together, the lipopeptides obtained from strain UL-1 demonstrated a potent anti-Fusarium effect inducing morphological alterations and antibiofilm activities. Our data open further studies for the biotechnological application of these lipopeptides as potential antifungal agents. KEY POINTS: • Lipopeptides inhibit Fusarium growth and induce chlamydospore-like structures. • Lipopeptides hamper the adherence of conidia and biofilms of Fusarium solani. • Iturins, fengycins, and surfactins were associated with antifungal effects.

Indexed as

Antifungal AgentsBacillus subtilisBiofilmsFusariumLipopeptidesPeptides, CyclicPlant DiseasesSpores, FungalAntifungal AgentsLipopeptidesPeptides, CyclicAntifungal activityBacillus subtilisFengycinFusariumIturinLipopeptidesSurfactin

Identifiers

PMID37561179
OpenAlexW4385716513

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.